Head-to-head · WeighScore
Measured vs Zealthy
The verdict
Measured takes it — 75.1/100 to 46.7/100.
Measured grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Measured is a metabolic-health membership pairing GLP-1 treatment with 1:1 nutrition support and board-certified provider care.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Measured | Zealthy |
|---|---|---|
| WeighScore | 75.1/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #58 | #496 |
| Semaglutide | $119/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $219/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #58 · C
Strengths
- Membership includes 1:1 nutrition support and board-certified provider care
- Both compounded (from $79/mo microdose, $119 semaglutide, $229 tirzepatide) and brand-name Wegovy/Zepbound
- Insurance or cash-pay options for brand-name medications
- Oral option available (Wegovy pill); cancel-anytime membership
Where it loses points
- The headline $79 'GLP-1 Microdose' is a promotional rate off a $99 list price, is filed by the provider under longevity rather than weight loss, and is not a labelled therapeutic dose of either molecule
- Branded plans are a $49/mo membership with the medication billed separately at $149 to $449/mo
- The site never states which billing term its 'from' prices assume, though the terms allow monthly, quarterly, semi-annual and annual
- No state count is published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.